Q-omics provides the consensus-scored DPEP3 profile across patient tissues and cancer cell-line models. DPEP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DPEP3 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, DPEP3 RNA expression shows 7,505 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight HNSC, COAD, and PAAD as cancer lineages where DPEP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPEP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPEP3 survival associations across molecular data types. DPEP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPEP3 RNA expression–survival associations across cancer types. High DPEP3 expression shows unfavorable associations in ACC, but favorable associations in HNSC, SKCM, MESO, ESCA and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DPEP3 RNA expression.
This table summarizes DPEP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DPEP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPEP3 shows lower tumor expression in COAD, BRCA, THCA, LUAD and LIHC and higher tumor expression in KIRC. The COAD box plot shows higher DPEP3 RNA expression in normal versus tumor tissue (log2 FC = −0.436, t-test p < 0.001).
This table shows molecular features associated with DPEP3 in patient tissues and cancer cell lines. In patient samples, DPEP3 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DPEP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
